Media

Vicore Pharma raises approximately SEK 782 million through an oversubscribed rights issue

BONESUPPORT – Additional data from SOLARIO study reveals further positive insights

Vicore Announces Investment from Sanofi

InCarda Therapeutics Announces Results From the RESTORE-1 Phase 3 Trial and Plans for Continued Development

BONESUPPORT – SOLARIO study meets its primary endpoints – Bone substitute with local antibiotics enables reduced systemic antibiotic treatment

Vicore Publishes Prospectus Relating to the Rights Issue

Vicore Announces Additional Subscription Undertaking from HealthCap

Oncopeptides signs license agreement with SCBIO for Pepaxti in South Korea

Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases

Vicore Initiates the Global, Randomized Phase 2b ASPIRE Trial Evaluating the Disease-Modifying Potential of Buloxibutid in Idiopathic Pulmonary Fibrosis